5CampbeU DJ.The Kallikrein-kinin system in humans [J].Clin Exp Pharmacol Physiol, 2001,28 ( 12 ) : 1060-1065.
6Leeb-Lundberg LM, Marceau F, M u ller-Esterl W, et al.Intemafional union of pharmacology.XLV.Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences [J]. Pharmacol Rev, 2005,57 ( 1 ) : 27-77.
7Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCJ-186), on acute brain infarction.Randomized, lacebo-controlled, double-blind study at multicenters.Cerebrovasc Dis, 2003, 15: 222 - 229.
8Takamatsu Y, Yuki S, Watanabe T. Studies on the concentration of 3 -methyl-1-1 phenyl-2-pyrazolin-5 -one (MCI-186) in MCA occlusion and reperfusion model of rats. Jpn Pharmacol Ther, 1997, 25(Suppl): S1785 - S1791.
9Jin YJ, Mima T, Raicu V, et al. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res, 2002, 43:75 -79.
10Felberg RA, Burgin WS, Grotta JC. Neuroprotection and the ischemic cascade. CNS Spectrums, 2000, 5:52 -58.
7Chun Fangxia, Hang Yin, Cesar V, et al. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis[J]. Hypertension, 2004,43:452- 459.
8Zhang Canfei. Efficacy and safety of human urinary kallidinoge- nase[J]. J Evidence - Based Medicine, 2012,5 (1) : 31 - 39.
